课题基金 / 基金详情

IGFBP7 - A Novel Biomarker, and a Clue to the Pathophysiology of Heart Failure with Preserved Ejection Fraction?

IGFBP7 - A Novel Biomarker, and a Clue to the Pathophysiology of Heart Failure with Preserved Ejection Fraction?
IGFBP7 - 一种新型生物标志物，以及射血分数保留的心力衰竭病理生理学的线索？
批准号：
321750
负责人：
Liu Peter P
金额：
$43.35万
依托单位：
Ottawa Heart Institute Research Corporation (Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-03-01 至 2020-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=321750&lang=en
关键词：
Biomarker Heart Failure Innate Immunity Senescence Therapy

项目摘要

项目成果

Liu Peter P的其他基金

相似基金

相关文献

中文摘要
翻译
心力衰竭，或心脏功能逐渐恶化，为身体其他部位供血，影响五分之一的加拿大人，每年造成超过10万人死亡。 这是最昂贵的医疗条件。 虽然传统的形式
英文摘要
Heart failure, or progressive deterioration of heart function to supply blood to the rest of the body, affects 1 in 5 Canadians, and accounts for over 100,000 deaths a year in Canada. It is the most costly medical condition. While the traditional form
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations
COVID-19 Variant Supplement - Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
COVID-19 Vaccine-Induced Inflammatory Heart Disease Prevalence Registry and Cohort Study (COVID-VIHPR)
Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
海外基金